1Department of Neurosurgery, Southwest Hospital, Third Military Medical University (Army Medical University), Chongqing; and.
2Department of Cerebrovascular Disease, Dazhou Central Hospital, Dazhou, China.
J Neurosurg Spine. 2022 Jul 1;37(6):905-913. doi: 10.3171/2022.3.SPINE211437. Print 2022 Dec 1.
Tarlov cysts (TCs) are a common cystic entity in the sacral canal, with a reported prevalence between 1.5% and 13.2%; 10%-20% of patients are symptomatic and need appropriate clinical intervention. However, the choice of treatment remains controversial. The goal of this study was to describe a new microsurgical sealing technique for symptomatic sacral TCs (SSTCs) as well as its long-term outcomes.
Microsurgical sealing was performed using a short incision, leakage coverage with a piece of autologous fat, and cyst sealing with fibrin glue. Postoperative data were collected at three stages: discharge, 1-year follow-up, and a follow-up of 3 years or more. According to the improvement in neurological deficits and degree of pain relief, outcomes were divided into four levels: excellent, good, unchanged, and deteriorated.
A total of 265 patients with SSTCs were treated with microsurgical sealing from January 2003 to December 2020. The mean follow-up was 44.69 months. The percentages of patients who benefited from the operation (excellent and good) at the three stages were 87.55%, 84.89%, and 80.73%, respectively, while those who received no benefit (unchanged and deteriorated) were 12.45%, 15.11%, and 19.27%, respectively. Of the patients with postoperative MRI, the cysts were reduced in size or disappeared in 209 patients (94.14%). CSF leakage from the wound was observed in 15 patients, and 4 patients experienced an infection at the incision. There were no cases of new-onset nerve injury or aseptic meningitis after the operation.
SSTC patients undergoing microsurgical sealing had persistently high rates of symptom relief and few postoperative complications. Microsurgical sealing is an effective, simple, and low-risk method for treating SSTCs.
Tarlov 囊肿(TCs)是椎管内常见的囊性病变,其报道的患病率为 1.5%至 13.2%;10%-20%的患者有症状并需要适当的临床干预。然而,治疗方法的选择仍存在争议。本研究的目的是描述一种新的治疗症状性骶管 TCs(SSTCs)的显微外科密封技术及其长期疗效。
采用短切口、自体脂肪片覆盖漏口、纤维蛋白胶封闭囊肿的方法进行显微外科密封。收集术后三个阶段的数据:出院时、1 年随访时和 3 年以上随访时。根据神经功能缺损的改善和疼痛缓解程度,将疗效分为四级:优、良、无变化和恶化。
2003 年 1 月至 2020 年 12 月,采用显微外科密封技术治疗了 265 例 SSTCs 患者。平均随访时间为 44.69 个月。在三个阶段,从手术中获益(优和良)的患者比例分别为 87.55%、84.89%和 80.73%,而未获益(无变化和恶化)的患者比例分别为 12.45%、15.11%和 19.27%。术后行 MRI 检查的患者中,209 例(94.14%)囊肿体积缩小或消失。15 例患者出现伤口脑脊液漏,4 例患者切口感染。术后无新发神经损伤或无菌性脑膜炎病例。
接受显微外科密封术的 SSTC 患者的症状缓解率持续较高,术后并发症较少。显微外科密封术是治疗 SSTCs 的一种有效、简单、低风险的方法。